Lars Ronn Olsen
Overview
Explore the profile of Lars Ronn Olsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
716
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Treon S, Kotton C, Park D, Moranzoni G, Lemvigh C, Gathe Jr J, et al.
Front Immunol
. 2025 Feb;
15:1369619.
PMID: 39906744
Background: Cytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)-related respiratory failure. Bruton tyrosine kinase (BTK) is involved in...
2.
Martinenaite E, Lecoq I, Aaboe-Jorgensen M, Ahmad S, Perez-Penco M, Glockner H, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39880485
Background: Arginase-1 (Arg1) expressing tumor-associated macrophages (TAMs) may create an immune-suppressive tumor microenvironment (TME), which is a significant challenge for cancer immunotherapy. We previously reported the existence of Arg1-specific memory...
3.
Maurer K, Park C, Mani S, Borji M, Raths F, Gouin 3rd K, et al.
Sci Immunol
. 2025 Jan;
10(103):eadr0782.
PMID: 39854478
Understanding how intratumoral immune populations coordinate antitumor responses after therapy can guide treatment prioritization. We systematically analyzed an established immunotherapy, donor lymphocyte infusion (DLI), by assessing 348,905 single-cell transcriptomes from...
4.
Perez-Penco M, Byrdal M, Lara de la Torre L, Ballester M, Khan S, Siersbaek M, et al.
Cell Mol Immunol
. 2024 Dec;
22(1):111-126.
PMID: 39653766
Although interleukin (IL)-6 is considered immunosuppressive and tumor-promoting, emerging evidence suggests that it may support antitumor immunity. While combining immune checkpoint inhibitors (ICIs) and radiotherapy in patients with pancreatic cancer...
5.
Shinde P, Willemsen L, Anderson M, Aoki M, Basu S, Burel J, et al.
bioRxiv
. 2024 Sep;
PMID: 39282381
Systems vaccinology studies have been used to build computational models that predict individual vaccine responses and identify the factors contributing to differences in outcome. Comparing such models is challenging due...
6.
Aehnlich P, Velasco Santiago M, Dam S, Salo S, Rahbech A, Olsen L, et al.
Cytotherapy
. 2024 May;
26(9):1033-1045.
PMID: 38775775
Background Aims: Vγ9Vδ2 T cells are under investigation as alternative effector cells for adoptive cell therapy (ACT) in cancer. Despite promising in vitro results, anti-tumor efficacies in early clinical studies...
7.
Shinde P, Soldevila F, Reyna J, Aoki M, Rasmussen M, Willemsen L, et al.
Cell Rep Methods
. 2024 Mar;
4(3):100731.
PMID: 38490204
Systems vaccinology studies have identified factors affecting individual vaccine responses, but comparing these findings is challenging due to varying study designs. To address this lack of reproducibility, we established a...
8.
Maurer K, Park C, Mani S, Borji M, Penter L, Jin Y, et al.
bioRxiv
. 2024 Feb;
PMID: 38405900
Understanding how intra-tumoral immune populations coordinate to generate anti-tumor responses following therapy can guide precise treatment prioritization. We performed systematic dissection of an established adoptive cellular therapy, donor lymphocyte infusion...
9.
Eickhardt-Dalboge C, Nielsen H, Fuursted K, Stensvold C, Andersen L, Lilje B, et al.
Eur J Haematol
. 2024 Jan;
112(5):776-787.
PMID: 38226781
Background: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota...
10.
Pedersen C, Campos B, Rene L, Wegener H, Krishnan N, Panda B, et al.
Mol Oncol
. 2023 Dec;
18(3):606-619.
PMID: 38158740
Molecular subtyping is essential to infer tumor aggressiveness and predict prognosis. In practice, tumor profiling requires in-depth knowledge of bioinformatics tools involved in the processing and analysis of the generated...